 |
David Thomas, PhD
David has thirty years experience in biotechnology, fifteen
of which were spent at major biopharmaceutical companies. His
last position was as Senior Vice President Research &
Development at Tanox, Inc. Before that, he was at Biogen
as Director of Cell Biology and Immunology. He is an
inventor on 64 patent publications and author of over 100
scientific publications in the area of immunology.
|
 |
James W. Larrick , MD PhD
Jim has an international reputation in biotechnology having
worked on various aspects of therapeutic antibodies and other
protein therapeutics for the past 20 years. During this time he has
written or co-authored eight books, over 220 papers/chapters and
fifteen patents. He serves on the editorial board of six journals.
Dr Larrick. Dr Larrick received his M.D. and Ph.D. degrees from Duke
University School of Medicine, Durham, NC. After having completed a
post-doctoral fellowship with Prof. Henry S. Kaplan in Stanford, he
joined Cetus Immune Research Labs, Palo Alto, CA, where he became
Director of Research in 1986. While at Cetus he pioneered the use of
PCR for the construction of recombinant antibodies. In 1991, Dr
Larrick founded the Palo Alto Institute of Molecular Medicine, a
non-profit research institute situated near Stanford University.
Since then he has founded more than a dozen biopharmaceutical
companies including Kalobios and Nugen Technologies in California
and PanGenetics B.V. and TargetQuest B.V. (merged with Dyax Inc.)
in The Netherlands. Currently he serves on the Boards of five
early stage companies and continues to pursue entrepreneurial
activities through TENEX Medical Investors in Silicon Valley and 7X,
an investment fund he co-founded in The Netherlands.
|
 |
Randy Noelle, PhD
Randy is Professor of microbiology and immunology at
Dartmouth Medical School and deputy director of the Norris
Cotton Cancer Center, as well as co-director of the center's
Immunology and Cancer Immunotherapy Research Program. He was a
post-doctoral fellow at the University of Texas Health Science
Center at Dallas from 1980-1984, and in 1984, he joined the
faculty of Dartmouth Medical School as an Assistant Professor.
In 1995, he was promoted to Professor of Microbiology. His
laboratory has identified a novel membrane protein expressed on
helper T lymphocytes (Th), CD154. Research is focused on how to
block a wide spectrum of immune and autoimmune responses and
transplantation rejection.
|
 |
Flavio Vincenti, MD
Flavio is Professor of Clinical Medicine at UCSF, and is a
kidney and pancreas transplant specialist. He came to UCSF Medical Center in 1975 for a transplant nephrology
fellowship and was appointed a member of the kidney transplant
team. His memberships in professional organizations include the
American Society of Nephrology, American Society of
Transplantation, International Society of Nephrology and
Transplantation Society. He is a co-leader of the kidney
section of the Immune Tolerance Network for kidney
transplantation. In addition, he is on the editorial board of the
American Journal of Kidney Diseases and Graft. In 1978, Vincenti
was one of the authors of an article in the New England Journal
of Medicine about the role of blood transfusions in improving
kidney transplants. He also wrote a series of articles on the
complications of transplants and has been a leading
investigator and author on the use of anti-interleukin-2
receptor monoclonal antibodies.
|
 |
Nabil Hanna, PhD
Nabil Hanna, Ph.D. has served as Executive Vice
President, Research of Biogen-Idec since the merger in November
2003. Dr Hanna joined Idec in 1990 as VP of R&D and was Idec’s
Chief Scientific Officer from May 1998 to November 2003. From
1981 to 1990, Dr Hanna served as Associate Director and then
Director of the Department of Immunology at SmithKline Beecham,
focusing on autoimmune and chronic inflammatory diseases. From
1978 to 1981, he was a research scientist at the NCI-Frederick
Cancer Research Center, where he studied the role of immune system
cells in host defenses against cancer. From 1973 to 1978, Dr
Hanna was a lecturer in the Department of Immunology at the Hebrew
University Medical School in Israel, where he received his Ph.D. in
Immunology.
|
